Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
Caribou Biosciences, the CAR-T biotech co-founded by Jennifer Doudna, is ending R&D activities and cutting staff as financing conditions tighten.
Caribou Biosciences
NASDAQ: CRBU $0.47 USD
Clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies for hematologic malignancies, built on its CRISPR platform.
Company Info
Sector:Cell Therapy / Gene Editing
Headquarters:Berkeley, California, United States
Founded:2011
Website:www.cariboubio.com/
Upcoming Milestones & Key Dates
2026-10
Corporate
R&D activities wind-down and staff reductions announced
Clinical Development Pipeline
CB-010
Target: CD19CB-011
Target: BCMAWorkforce & Restructuring Tracker
View Industry Layoff Tracker →87 roles (90%)WARN Notice
CRISPR pioneer Caribou Biosciences ceased all clinical development across its off-the-shelf allogeneic ex vivo CAR-T pipeline (including vispa-cel and CB-011), laying off 87 of 97 employees (~90% of staff) per California WARN filings to explore strategic alternatives.
Recent News
Leadership Team
Rachel Haurwitz
President and Chief Executive Officer
Tina Albertson
Chief Medical Officer
Sri Ryali
Chief Financial Officer